Malaria Vaccines Market, By Agent Type (Plasmodium Falciparum, Plasmodium Vivax, and Anopheles Species), By Vaccine Type (Pre-Erythrocytic Vaccine, Erythrocytic Vaccine, and Multi-antigen Vaccine), By Distribution Channel (Hospitals, Clinics, and Community Centers), and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Trends, Analysis and Forecast till 2032

Malaria vaccines market was valued at USD 2.4 million in 2022 and is expected to reach USD 52.8 million by 2032, registering a CAGR of 34.1% during the forecast period

The parasite Plasmodium, which is spread by mosquitoes and infects humans through bites, causes the disease known as malaria. A biological component that encourages the production of antibodies is referred to as the malaria vaccine. Symptoms of malaria include chills, fever, tiredness, headaches, nausea, and so forth. The vaccine may be administered intradermally, subcutaneously, or intramuscularly. There are three main types of immunizations: multi-antigen, erythrocytic, and pre-erythrocytic vaccinations.

The global market for malaria vaccines is primarily being driven by the rise in malaria prevalence, especially in tropical nations. Numerous government and non-governmental groups are launching encouraging efforts to inform people about illness prevention and the need for vaccinations, particularly in endemic and rural areas. Thus, these elements are now primarily responsible for the market expansion for malaria vaccines. The need for malaria vaccinations has increased due to the emergence of pre-erythrocytic vaccines, sometimes called anti-infective vaccines, which target the plasmodium parasite and stop the evolution of chronic blood-stage disorders.